BRAINLIFE Brain Tumor Medical Database

Staging and Prognosis | Treatment > Radiosurgery


J Neurosurg. 2005 Jan;102 Suppl:102-6. (Retrospective Study)


Abstract

Gamma knife surgery for intracranial cavernous hemangioma

Kim MS, Pyo SY, Jeong YG, Lee SI, Jung YT, Sim JH

Department of Neurosurgery, University Busan Paik Hospital, Busan, South Korea. kinmmo@yahoo.co.kr

Object. The purpose of this study was to assess the benefits of radiosurgery for cavernous hemangioma. 

Methods. Sixty-five cavernous hemangiomas were treated with gamma knife surgery (GKS) between October 1994 and December 2002. 
Forty-two patients attended follow up. 
The mean patient age was 37.6 years (range 7-60 years). 
The lesions were located in the frontal lobe in 12 cases, deep in the parietal lobe in five, in the basal ganglia in five, in the temporal in three, in the cerebellum in three, in the pons/midbrain in six, and in multiple locations in eight cases. 
The presenting symptoms were seizure in 12, hemorrhage in 11, and other in 19. 
The maximum dose was 26.78 Gy, and the mean margin dose was 14.55 Gy. 
The mean follow-up period after radiosurgery was 29.6 months (range 5-93 months). 
The tumor decreased in size in 29 cases, was unchanged in 12, and increased in size in one. 
In the seizure group, seizures were controlled without anticonvulsant medication in nine cases (81.8%) after 31.3 months (range 12-80 months). 
After 93 months, one patient developed a cyst, which was resected. 
Rebleeding occurred in one case (2.3%). 
On T2-weighted imaging changes were seen in 11 cases (26.2%), in three (7.1 %) of which neurological deterioration was correlated with imaging changes. In other cases these deficits were temporary. 

Conclusions. The authors found that GKS was an effective treatment modality for cavernous hemangiomas, especially for those located within the brainstem, basal ganglia, or deep portions of the brain. It can reduce seizure frequency significantly although this takes time. In the group receiving a marginal dose below 15 Gy the patients fared better than when the dose exceeded 15 Gy.

PMID: 15662789 [PubMed - indexed for MEDLINE]

Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15662789



 

This website is certified by Health On the Net Foundation. Click to verify. HOMECURRENT NEURO-ONCOLOGYGLIOBLASTOMA REPORTSBRAIN TUMOR MEDICAL DATABASE SERVICES TREATMENT OPTIONS FOR GLIOBLASTOMA
DATABASE by Section: Classification | Diagnosis | Epidemiology | Etiology & Pathogenesis | Integrative Medicine | Overall Management | Prognosis | Psychosocial Aspects | Stem Cells | Treatment
DATABASE by Tumor: Glioblastoma | Medulloblastoma | Other TumorsSERVICES: About BrainLife | Children's Corner | Dedication | E-mail Alerts | Journals | Privacy Policy | Publications | Search | SiteMap
This site complies with the HONcode standard for trustworthy health information: verify here bottom